PPT-Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes

Robert J Mentz M Angelyn Bethel Peter Merrill Yuliya Lokhnygina John B Buse Juliana C Chan Jasmine Choi Stephanie M Gustavson Nayyar Iqbal Aldo P Maggioni Steven P Marso Peter . periodontium. . . Endocrine diseases such as diabetes and hormonal . fluctuations,that. are associated with puberty and pregnancy are well known examples of systemic conditions that . adversally. Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. With GLP-1 RAs. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form.. . These data should be considered preliminary until published in a . M. Angelyn Bethel, MD. Associate Professor of Diabetes and Endocrinology. Deputy Director, Diabetes Trials Unit. University of Oxford. for the International Diabetes Federation Congress. 6. th. December, . results in increased concentrations of glucose in the blood, which in turn damage the blood vessels and nerves.. Diabetes mellitus is a group of metabolic disorders sharing the common feature of . hyperglycemia. This . topic will review the pathogenesis of hypertension in patients with diabetes mellitus and the three major treatment issues:. The evidence supporting benefit from the treatment of hypertension. 01/12/2019. 1. 2. How this lecture will work. Overview. of topics (prioritised and simplified). Key, important points are written on the slides. Everything I say, including some extra details (that you almost defo don’t need), will be in the notes at the bottom - no need to make your own notes!. 2018 ADA GUIDELINES. Dr. . Sanjana. Bhagwat. Moderator : Dr. S. . Jotkar. Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. 116 SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality Scottish Intercollegiate Guidelines NetworkManagement of diabetesA 99 Vol.6; Issue: 7; July 2016 International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249 - 9571 Original Research Article Musculoskeletal Disorders in Patients with Type 2 Diabet 215 Introduction: Musculoskeletal complications are most seen in patients with a longstanding history of DM type 1. Aim: This study aimed to determine the prevalence of musculoskeletal manifestations TECOS Executive Committee MemberRury R. Holman, MB, ChBDiabetes Trials Unit, OCDEM Churchill Hospital, Oxford, United KingdomTECOS CoPrincipal Investigator andJoint Chair of TECOS Executive CommitteeR DR. EBARE C KELVINS. SENIOR MEDICAL OFFICER. NHIS/GMS. FEDERAL NEUROPSYCHIATRIC HOSPITAL, BENIN.. Definition. Epidemiology. Classification . Pathogenesis. Clinical features. Investigations. Diagnosis . Farzad. . Hadaegh. , MD, . Professor of Internal Medicine & Endocrinology. Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences. Shahid. . Beheshti. University of Medical Sciences .